InflaRx (IFRX) Return on Sales (2018 - 2026)

InflaRx (IFRX) posted Return on Sales of 0.04% for Q1 2026, up 477.84% sequentially from 0.01% in Q4 2025, and up 351.0% YoY from 0.01% in Q1 2025.

InflaRx (IFRX) Return on Sales (2018 - 2026) Analysis & Trends

InflaRx has reported Return on Sales for 9 years, with the latest figure at 0.04% in Q1 2026.

Quarterly Return on Sales rose 351.0% year-over-year to 0.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.01%, changed 0.0% from the prior year.
Return on Sales improved to 0.04% in Q1 2026 per IFRX's latest filing, from 0.01% in the prior quarter.
Over five years, Return on Sales peaked at 0.15% in Q1 2022 and troughed at 22.9% in Q2 2024.
A 5-year average of 2.22% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
The sharpest annual moves came in 2022 and 2025: Return on Sales tumbled 6130 bps in 2022, then jumped 1975 bps in 2025.
Over 5 years, Return on Sales stood at 0.42% in 2022, then soared by 99 bps to 0.0% in 2023, then soared by 404 bps to 0.01% in 2024, then declined by 11 bps to 0.01% in 2025, then soared by 478 bps to 0.04% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 0.04%, 0.01%, and 3.78% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.00%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	0.00%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	0.00%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.00%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.00%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.00%
10	InflaRx	135.25 Mn	-49.00 Mn	2.74 Bn	-1.59%

Download Data